Kai Lin

Chief Scientific Officer @ HEC Pharm Co., Ltd.

About

• 25 years of drug discovery & development experience in pharmaceutical industry that led to 16 INDs and 2 NDAs • Led both small molecule and biologics drug development, including siRNA, antibody, and protein therapeutics • Built and managed multiple high-performing research and cross-functional teams • Experienced in managing external partnership, academic collaboration and CROs • Played major roles in developing therapeutic strategies and in-/out-licensing • Involved in Phase 1-3 clinical trial design, protocol review and study support • Closely interacted with KOLs and regulatory agencies including FDA and EMA • Authored 50 peer-reviewed papers/book chapters and listed as inventors on 30+ patents

Country

United States

City

Greater Boston

Industry

Pharmaceuticals

Skill

Drug Discovery, Biotechnology, Pharmaceuticals, Clinical Development, Virology, Cell biology, Oncology, Lifesciences, Infectious Diseases, Pharmaceutical Industry, Molecular Biology, Assay Development, Cell Biology, Immunology, Clinical Research, Medical Writing, Drug Development, High Throughput Screening, Clinical Trials, Cancer

Experience

Chief Scientific Officer

HEC Pharm Co., Ltd.

2024-12 - Present · 1 yr 10 mos

Small molecule, siRNA, antibody, and cell therapy Anti-infectives, metabolic & liver diseases, and oncology

Board Member

AOC Biosciences

2023-10 - Present · 3 yrs

Antibody oligonucleotide conjugates Neuromuscular disorders, rare diseases

Scientific Advisor

Lerna Biopharma

2023-7 - 2024-9 · 1 yr 3 mos

siRNA therapeutics MASH, liver regeneration

Senior Vice President, Head of Research

Aerium Therapeutics

2022-6 - 2024-6 · 2 yrs 1 mo

Boston, Massachusetts, United States

Responsible for both monoclonal antibody and small molecule drug discoveries AER001/002 (Ph1)

Vice President

Atea Pharmaceuticals, Inc

2020-11 - 2022-6 · 1 yr 8 mos

Boston, Massachusetts, United States

COVID-19, Dengue, RSV AT-527 (Ph3), AT-752 (Ph1)

Senior Director

Enanta Pharmaceuticals

2015-1 - 2020-11 · 5 yrs 11 mos

Watertown, Massachusetts

Respiratory infections, liver diseases EDP-938 (Ph2), EDP-514 (Ph2), EDP-721 (Ph1), EDP-235 (Ph1), EDP-323

Executive Director, Biology and Translational Science

Merck

2014-5 - 2014-12 · 8 mos

Cambridge, Massachusetts

Virology, oncology Uprifosbuvir/MK-3682 (Ph2)

Director of Biology

Permeon Biologics, Inc, a Flagship Company

2012-6 - 2014-5 · 2 yrs

Cambridge, Massachusetts

Antibody-drug conjugates (ADC), protein therapeutics Oncology, rare diseases

Senior Investigator II, Group Head (2006-2012), Lab Head (2004-2006)

Novartis

2004-5 - 2012-6 · 8 yrs 2 mos

Cambridge, Massachusetts, United States

• Built and managed a research group of 14 PhD and non-PhD scientists • Led multiple cross-functional project teams that involved chemistry, biology, DMPK, toxicology, CMC and TM • Closely interacted with health authorities (FDA, EMA and sFDA) and KOLs • Played a major role in developing portfolio and evaluating in-licensing opportunities • Managed external partnership, academic collaboration and CROs • Tyzeka/Sebivo/Telbivudine (NDA), alisporivir/Debio-025 (Ph3), NIM811 (Ph2), NM-282 (Ph2), EDP-239 (Ph2), BZF961 (Ph1), LDI133, RSV604 (Ph2)

Staff Investigator (2002-2004), Investigator (2000-2002)

Vertex Pharmaceuticals

2000-1 - 2004-5 · 4 yrs 5 mos

• Responsible for biology support for the HCV protease program - a key contributor to the discovery of Incivek/Telaprevir/VX-950, the first approved antiviral drug for HCV • Involved in multiple kinase programs for oncology indications: established in vitro and cell-based kinase assays and performed signal transduction and cell cycle analysis • Provided preclinical support for the development of IMPDH inhibitors, Merimepodib/VX-497 (Ph2), VX-944 (Ph1)